Sign in to follow this  
Followers 0
Joelf

Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (pSS) open-label proof of concept ASAP study).

1 post in this topic

Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (pSS) open-label proof of concept ASAP study).

 

Abatacept is effective, safe and well tolerated. It results in improved disease activity, laboratory parameters, fatigue and health-related quality of life in patients with early and active pSS. PubMed, Ann rheumatologist Dis, 2014 Jan 28. (Also see: Sjogren's Syndrome)

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.


Jo Frowde

ISN Assistant Webmaster

SD World Webmaster

ISN Sclero Forums Manager

ISN News Manager

ISN Hotline Support Specialist

International Scleroderma Network (ISN)

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!


Register a new account

Sign in

Already have an account? Sign in here.


Sign In Now
Sign in to follow this  
Followers 0